Based on the Adial Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Adial Pharmaceuticals Inc is not available over the next 12 months. Adial Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Adial Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Adial Pharmaceuticals Inc’s stock price was USD 0.69. Adial Pharmaceuticals Inc’s stock price has changed by -3.38% over the past week, -6.92% over the past month and -68.39% over the last year.
No recent analyst target price found for Adial Pharmaceuticals Inc
No recent average analyst rating found for Adial Pharmaceuticals Inc
Company Overview Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia. Read Less
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trial...Read More
Frequently Asked Questions About Adial Pharmaceuticals Inc (ADIL) Stock
Stock Target Advisor's fundamental analysis for Adial Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on ADIL's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ADIL's stock to indicate what its average analyst target is.
ADIL stock's Price/Earning ratio is 0.02.
Our analysis grades ADIL stock's Price / Earning ratio at A-. This means that ADIL stock's Price/Earning ratio is above 9.999999999999998% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ADIL may be undervalued for its sector.
The last closing price of ADIL's stock was USD 0.69.
The most recent market capitalization for ADIL is USD 4.67M.
Unfortunately we do not have enough analyst data on ADIL's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Adial Pharmaceuticals Inc's stock.
As per our most recent records Adial Pharmaceuticals Inc has 5 Employees.
Adial Pharmaceuticals Inc's registered address is 4870 Sadler Road, Glen Allen, VA, United States, 23060.
You can get more information about it from Adial Pharmaceuticals Inc's website at https://www.adial.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Adial Pharmaceuticals Inc (ADIL) Stock
Stock Target Advisor's fundamental analysis for Adial Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on ADIL's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ADIL's stock to indicate what its average analyst target is.
ADIL stock's Price/Earning ratio is 0.02.
Our analysis grades ADIL stock's Price / Earning ratio at A-. This means that ADIL stock's Price/Earning ratio is above 9.999999999999998% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ADIL may be undervalued for its sector.
The last closing price of ADIL's stock was USD 0.69.
The most recent market capitalization for ADIL is USD 4.67M.
Unfortunately we do not have enough analyst data on ADIL's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Adial Pharmaceuticals Inc's stock.
As per our most recent records Adial Pharmaceuticals Inc has 5 Employees.
Adial Pharmaceuticals Inc's registered address is 4870 Sadler Road, Glen Allen, VA, United States, 23060.
You can get more information about it from Adial Pharmaceuticals Inc's website at https://www.adial.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ADIL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
